Comparison of utilisation and costs of treatment for patients with type 2 diabetes using insulin glargin or insulin detemir: A claims data analysis using the propensity score matching method;Ressourcen-inanspruchnahme und kosten der behandlung von typ-2-diabetikern unter insulin-glargin- oder insulindetemir-therapie (LIVE-KK1): Analyse von krankenkassen-routinedaten mittels propensity score matching

Gesundheitsokonomie und Qualitatsmanagement

Volumn 15, Issue 3, 2010, Pages 121-126

  Hagenmeyer, E G ^a   Gothe, H ^a,c   Landgraf, W ^b   Kulik, M ^a   Schiffhorst, G ^a   Haussler B ^a  

^a IGES Institut fur Gesundheits und Sozialforschung GmbH   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Cost comparison; Insulin detemir; Insulin glargine; Routine data analysis; Type 2 diabetes

Indexed keywords

INSULIN DETEMIR; INSULIN GLARGINE;

ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; SCORING SYSTEM;

EID: 77953153815     PISSN: 14322625     EISSN: 14394049     Source Type: Journal    
DOI: 10.1055/s-0028-1110023     Document Type: Article

References (8)

1. Häussler B, Hagenmeyer E G., Storz P et al. Weißbuch Diabetes in Deutschland. Bestandsaufnahme und Zukunftsperspektiven der Versorgung einer Volkskrankheit. Stuttgart, New York Georg Thieme Verlag 2006
2. K0̈ster I, Ferber L von, Ihle P et al. The cost burden of diabetes mellitus: the evidence from Germany the CoDiM Study. Diabetologia 2006 49 1498-1504
3. Hauner H, K0̈ster I, Ferber L von. Prävalenz des Diabetes mellitus in Deutschland 1998 2001. Sekundärdatenanalyse einer Versichertenstichprobe der AOK Hessen/KV Hessen. Dts Med Wochenschr 2003 128 2632-2638
4. Häussler B, H0̈er A, Hempel E et al. Arzneimittel-Atlas 2007. Der Arzneimittelverbrauch in der GKV. München Urban und Vogel 2007
5. Porcellati F, Rossetti P, Busciantella N R. et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes. Diabetes Care 2007 30 2447-2452
6. Rosenstock J, Davies M, Home P D. et al. A randomised, 52-week, treat-to-target trial comparing Insulindetemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008 51 408-416
7. DAgostino R B. Tutorial in biostatistics. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine 1998 17 2265-2281
8. Hall J A., Summers K H., Obenchain R L. Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. Journal of Managed Care Pharmacy 2003 9 (3) 263-268